KRS Capital Management’s Edwards Lifesciences EW Stock Holding History

KRS Capital Management’s Portfolio EW Stock Details EW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$239K	Buy	2,645 +60	+2%	+$5.03K	0.11%	109
2026 Q1	$207K	Hold	2,585	–	–	0.13%	111
2025 Q4	$220K	Hold	2,585	–	–	0.13%	106
2025 Q3	$201K	Hold	2,585	–	–	0.12%	112
2025 Q2	$202K	Buy	+2,585	New	+$193K	0.14%	108
2024 Q3	–	Sell	-2,735	Closed	-$253K	–	119
2024 Q2	$253K	Hold	2,735	–	–	0.19%	101
2024 Q1	$261K	Sell	2,735 -365	-12%	-$30.7K	0.21%	101
2023 Q4	$236K	Sell	3,100 -480	-13%	-$33.4K	0.22%	104
2023 Q3	$248K	Sell	3,580 -345	-9%	-$27.7K	0.26%	93
2023 Q2	$370K	Buy	3,925 +100	+3%	+$8.69K	0.37%	75
2023 Q1	$316K	Hold	3,825	–	–	0.36%	82
2022 Q4	$285K	Buy	3,825 +200	+6%	+$15.4K	0.39%	82
2022 Q3	$299K	Buy	3,625 +20	+0.6%	+$1.92K	0.41%	73
2022 Q2	$342K	Hold	3,605	–	–	0.49%	69
2022 Q1	$424K	Buy	3,605 +50	+1%	+$5.61K	0.46%	64
2021 Q4	$460K	Buy	+3,555	New	+$415K	0.39%	66

Other funds holding EW

Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

Parnassus Investments San Francisco, California $37.4B AUM 35.42% 1-Year Est. Return

BHIA

Birch Hill Investment Advisors Boston, Massachusetts $2.47B AUM 20.95% 1-Year Est. Return

NONA

Ninety One North America New York $2.13B AUM 9.16% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

SIM

Seilern Investment Management London, United Kingdom $794M AUM 6.63% 1-Year Est. Return

KRS Capital Management's EW Position: Q2 2026 in Review

KRS Capital Management increased its Edwards Lifesciences (EW) stake by 2.3% in Q2 2026, buying an estimated $5.03K and bringing the position to 2,645 shares worth $239K. The position accounts for 0.11% of the portfolio, ranked #109.

KRS Capital Management first reported a position in EW in Q4 2021 and has held it in 16 quarters since. The position peaked at $460K in Q4 2021. 563 funds tracked by Wall St. Rank hold EW as of Q2 2026.

KRS Capital Management held 2,645 shares of Edwards Lifesciences worth $239K as of Q2 2026.
KRS Capital Management bought 60 Edwards Lifesciences shares in Q2 2026, an estimated $5.03K.
Edwards Lifesciences made up 0.11% of KRS Capital Management's portfolio in Q2 2026, its #109 holding.
KRS Capital Management first reported a position in Edwards Lifesciences in Q4 2021 and has held it in 16 quarters since.
KRS Capital Management's Edwards Lifesciences position peaked at $460K in Q4 2021.
563 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.

Based on KRS Capital Management's 13F filing for Q2 2026, filed 20 Jul 2026.